SRR15030862
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MITOTIC_SPINDLE+0.340
- G2M_CHECKPOINT+0.330
- HEDGEHOG_SIGNALING+0.280
- E2F_TARGETS+0.270
- MYC_TARGETS_V2+0.240
- HYPOXIA+0.150
- WNT_BETA_CATENIN_SIGNALING+0.150
- TGF_BETA_SIGNALING+0.140
- TNFA_SIGNALING_VIA_NFKB+0.110
- APICAL_JUNCTION+0.060
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.460
- OXIDATIVE_PHOSPHORYLATION-0.460
- INTERFERON_GAMMA_RESPONSE-0.450
- ADIPOGENESIS-0.380
- ALLOGRAFT_REJECTION-0.380
- PROTEIN_SECRETION-0.380
- FATTY_ACID_METABOLISM-0.350
- XENOBIOTIC_METABOLISM-0.350
- BILE_ACID_METABOLISM-0.340
- IL6_JAK_STAT3_SIGNALING-0.330
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_NB42PWZN | EPN | Supratentorial EPN | 0.857 |
| 2 | SRR33532765 | — | E | 0.852 |
| 3 | SRR17866827 | — | — | 0.851 |
| 4 | BS_NB42PWZN | Supratentorial Ependymoma | — | 0.836 |
| 5 | BS_SD8YBRBR | high-grade glioma | — | 0.834 |
| 6 | SRR6013518 | — | cohortSQ1 | 0.827 |
| 7 | TCGA-21-1081-01A-01R-0692-07 | — | cohortSQ1 | 0.815 |
| 8 | SRR10842373 | — | — | 0.808 |
| 9 | C3L-02358 | — | cohortSQ1 | 0.807 |
| 10 | SRR650136 | — | — | 0.805 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MITOTIC_SPINDLE | 0.340 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.330 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.280 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.270 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.240 | Idelalisib | — uncovered |
| HYPOXIA | 0.150 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.150 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.140 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.110 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.060 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.050 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.050 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.040 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.040 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.040 | Idelalisib | — uncovered |
| MYOGENESIS | 0.010 | Inavolisib | — uncovered |